Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.32 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | GRM8 | O00222 | 1/20 | 0.31 |
| ▸ | GRM6 | O15303 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5491826 | 0.96 | APLNR (0.35) | APLNRSLC1A2SLC1A1GRM4CYP2C19 | |
| SCHEMBL9754770 | 0.83 | GAA (0.31) | GAAL3MBTL1 | |
| SCHEMBL8599635 | 0.81 | CHRNB2 (0.32) | GAAL3MBTL1 | |
| SCHEMBL51127 | 0.81 | KMT2A (0.31) | KMT2AGAAL3MBTL1 | |
| SCHEMBL438903 | 0.79 | SLC1A2 (0.42) | APLNRSLC1A2SLC1A1ALDH1A1L3MBTL1 | |
| SCHEMBL13225976 | 0.78 | GAA (0.50) | APLNRSLC1A2SLC1A1GRM4CYP2C19 | |
| SCHEMBL4397787 | 0.78 | GAA (0.50) | APLNRSLC1A2SLC1A1GRM4CYP2C19 | |
| SCHEMBL697858 | 0.78 | GAA (0.50) | APLNRSLC1A2SLC1A1GRM4CYP2C19 | |
| SCHEMBL7634478 | 0.78 | APLNR (0.38) | APLNRSLC1A2SLC1A1GRM4CYP2C19 | |
| SCHEMBL1433982 | 0.78 | ATM (0.33) | CYP2C19CYP1A2MEN1KMT2ATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1403 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4714957-A1 | (METH)ACRYLATE COMPOUND PRODUCTION METHOD | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2026-03-25 | — | — | EP | claimed |
| EP-4100010-B1 | NITROXIDE COMPOUNDS FOR USE IN THE TREATMENT OF OPIOID-INDUCED RESPIRATORY DEPRESSION (OIRD) | UNIV CASE WESTERN RESERVE (US) | 2026-01-07 | — | — | EP | claimed |
| EP-4661890-A1 | PTP1B/TC-PTP DUAL INHIBITORS AND PROTEIN DEGRADERS | Purdue Research Foundation (US) | 2025-12-17 | — | — | EP | claimed |
| EP-4599224-A1 | RAPID GELLING AQUEOUS MOUNTING MEDIA | Life Technologies Corporation (US) | 2025-08-13 | — | — | EP | claimed |
| EP-3682222-B1 | REFRACTIVE INDEX MATCHING FORMULATIONS | LIFE TECHNOLOGIES CORP (US) | 2025-05-07 | — | — | EP | claimed |
| US-20250041285-A1 | MODIFYING THE EXPRESSION LEVEL OF A GENE ENCODING AN CYCLOOXYGENASE ENZYME BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HABASH LOUIS (US) | 2025-02-06 | — | — | US | claimed |
| US-12208089-B2 | Adjusting expression level of a gene encoding a Sirtuin protein by treating a human subject with a nitroxide | HABASH LOUIS (US) | 2025-01-28 | — | — | US | claimed |
| US-20240415826-A1 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING AN UNCOUPLING PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HABASH LOUIS (US) | 2024-12-19 | — | — | US | claimed |
| WO-2024237180-A1 | (METH)ACRYLATE COMPOUND PRODUCTION METHOD | 三菱瓦斯化学株式会社 | 2024-11-21 | — | — | WO | claimed |
| US-20240272049-A1 | REFRACTIVE INDEX MATCHING FORMULATIONS | LIFE TECHNOLOGIES CORP (US) | 2024-08-15 | — | — | US | claimed |
| US-5714510-A | Topical proxyl composition and method | PROCTOR PETER H (US) | 1998-02-03 | — | — | US | claimed |
| EP-0691329-B1 | Process for the preparation of polyencarbonyl compounds with high content of the all E-isomer and their acetals or ketales | BASF AG (DE) | 1997-10-29 | — | — | EP | claimed |
| EP-0797600-A1 | HIGH MOLECULAR WEIGHT POLYSTYRENE PRODUCTION BY VINYLACID CATALYZED FREE RADICAL POLYMERIZATION | THE DOW CHEMICAL COMPANY (US) | 1997-10-01 | — | — | EP | claimed |
| WO-1996018663-A1 | HIGH MOLECULAR WEIGHT POLYSTYRENE PRODUCTION BY VINYLACID CATALYZED FREE RADICAL POLYMERIZATION | THE DOW CHEMICAL COMPANY (US) | 1996-06-20 | — | — | WO | claimed |
| EP-0691329-A1 | Process for the preparation of polyencarbonyl compounds with high content of the all E-isomer and their acetals or ketales | BASF AKTIENGESELLSCHAFT (DE) | 1996-01-10 | — | — | EP | claimed |
| EP-0327263-B1 | Hair growth stimulation with nitroxide and other radicals | PROCTOR PETER H (US) | 1994-09-07 | — | — | EP | claimed |
| US-4925652-A | NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-05-15 | — | — | US | claimed |
| EP-0133674-B1 | NITROXYL COMPOUNDS, PROCESS FOR THEIR PREPARATION AND DIAGNOSTIC AGENTS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-09-20 | — | — | EP | claimed |
| US-4845090-A | NUCLEAR MAGNETIC RESONANCE | SCHERING AKTIENGESELLSCHAFT (DE) | 1989-07-04 | — | — | US | claimed |
| WO-1988005653-A1 | TOPICAL COMPOSITION FOR STIMULATING HAIR GROWTH WITH STABLE FREE RADICALS | PROCTOR PETER H (US) | 1988-08-11 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250041285-A1 | MODIFYING THE EXPRESSION LEVEL OF A GENE ENCODING AN CYCLOOXYGENASE ENZYME BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | HMOX2, QSOX1, GPX1 | APLNR 2550/4885SLC1A2 1502/4885SLC1A1 1461/4885 |
| US-12208089-B2 | Adjusting expression level of a gene encoding a Sirtuin protein by treating a human subject with a nitroxide | SIRT2, SIRT6, TXNRD2 | APLNR 2480/4885SLC1A2 2047/4885SLC1A1 2743/4885 |
| US-20240415826-A1 | MODULATING EXPRESSION LEVEL OF A GENE ENCODING AN UNCOUPLING PROTEIN BY TREATING A HUMAN SUBJECT WITH A NITROXIDE | TXNRD2, TXN2, TXNRD1 | APLNR 1889/4885SLC1A2 686/4885SLC1A1 1107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.